Quarterly report pursuant to Section 13 or 15(d)

Income taxes

v3.8.0.1
Income taxes
9 Months Ended
Sep. 30, 2017
Income Tax Disclosure [Abstract]  
Income taxes

4. Income taxes

During the three months ended September 30, 2017 and the nine months ended September 30, 2017 the Company recorded income tax expenses of 0.1 million and $1.0 million, respectively, representing an effective tax rate of (3.97%). The income tax expense is related the Company´s Australian jurisdiction, net of loss carryforwards, resulting from taxable income from the AstraZeneca Agreements.